FAFaria Ahmed

Faria Ahmed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Faria Ahmed has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Andrea Ibrahim

    Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada

    1 shared publication
  • Angela M. Crawley

    Inflammation Chronic Disease Program, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada

    1 shared publication
  • Ashok Kumar

    Indian Institute of Technology Kanpur

    1 shared publication
  • Charles N. Bernstein

    University of Manitoba IBD Clinical and Research Centre, University of Manitoba, Winnipeg, Canada

    1 shared publication
  • Curtis Cooper

    Ottawa Hospital Research Institute, Ottawa, ON K1Y 4E9, Canada

    1 shared publication
  • Eric I. Benchimol

    Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children (SickKids), Toronto, Canada; ICES, Toronto, Canada; Child Health Evaluative Sciences, SickKids Research Institute, The Hospital for Sick Children (SickKids), Toronto, Canada; Department of Paediatrics, University of Toronto, Toronto, Canada; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

    1 shared publication

Latest Publications

  • Open Access

    A Population-Based Matched Cohort Study of Digestive System Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease

    by Sanjay K. Murthy, Parul Tandon, Priscilla Matthews, Faria Ahmed, Michael Pugliese, Monica Taljaard, Gilaad G. Kaplan, Stephanie Coward, Charles Bernstein, Eric I. Benchimol, et al.

    INTRODUCTION: To study digestive system cancer risks in individuals with inflammatory bowel diseases (IBDs) in the biologic era. METHODS: We used population-level administrative and cancer registry data from Ontario, Canada, (1994–2020) to compare people with IBD to matched controls (1:10 by sex and birth year) on trends in age-sex standardized cancer incidence and risk ratios of incident cancers and cancer-related deaths. RESULTS: Among 110,919 people with IBD and 1,109,190 controls, colorectal cancer incidence (per 100,000 person-years) declined similarly in people with ulcerative colitis (average annual percentage change [AAPC] −1.81; 95% confidence interval [CI] −2.48 to −1.156) and controls (AAPC −2.79; 95% CI −3.44 to −2.14), while small bowel cancer incidence rose faster in those with Crohn's disease (AAPC 9.68; 95% CI 2.51–17.3) than controls (AAPC 3.64; 95% CI 1.52–5.80). Extraintestinal digestive cancer incidence rose faster in people with IBD (AAPC 3.27; 95% CI 1.83–4.73) than controls (AAPC −1.87; 95% CI −2.33 to −1.42), particularly for liver (IBD AAPC 8.48; 95% CI 4.11–13.1) and bile duct (IBD AAPC 7.22; 95% CI 3.74–10.8) cancers. Beyond 2010, the incidences (and respective mortality rates) of colorectal (1.60; 95% CI 1.46–1.75), small bowel (4.10; 95% CI 3.37–4.99), bile duct (2.33; 95% CI 1.96–2.77), and pancreatic (1.19; 95% CI 1.00–1.40) cancers were higher in people with IBD. DISCUSSION: Cancer incidence is declining for colorectal cancer and rising for other digestive cancers in people with IBD. Incidence and mortality remain higher in people with IBD than controls for colorectal, small bowel, bile duct, and pancreatic cancers.


  • Open Access

    Chronic Hepatitis C Virus Infection Impairs M1 Macrophage Differentiation and Contributes to CD8+ T-Cell Dysfunction

    by Faria Ahmed, Andrea Ibrahim, Curtis L. Cooper, Ashok Kumar, Angela M. Crawley

    Chronic hepatitis C virus (HCV) infection causes generalized CD8+ T cell impairment, not limited to HCV-specific CD8+ T-cells. Liver-infiltrating monocyte-derived macrophages (MDMs) contribute to the local micro-environment and can interact with and influence cells routinely trafficking through the liver, including CD8+ T-cells. MDMs can be polarized into M1 (classically activated) and M2a, M2b, and M2c (alternatively activated) phenotypes that perform pro- and anti-inflammatory functions, respectively. The impact of chronic HCV infection on MDM subset functions is not known. Our results show that M1 cells generated from chronic HCV patients acquire M2 characteristics, such as increased CD86 expression and IL-10 secretion, compared to uninfected controls. In contrast, M2 subsets from HCV-infected individuals acquired M1-like features by secreting more IL-12 and IFN-γ. The severity of liver disease was also associated with altered macrophage subset differentiation. In co-cultures with autologous CD8+ T-cells from controls, M1 macrophages alone significantly increased CD8+ T cell IFN-γ expression in a cytokine-independent and cell-contact-dependent manner. However, M1 macrophages from HCV-infected individuals significantly decreased IFN-γ expression in CD8+ T-cells. Therefore, altered M1 macrophage differentiation in chronic HCV infection may contribute to observed CD8+ T-cell dysfunction. Understanding the immunological perturbations in chronic HCV infection will lead to the identification of therapeutic targets to restore immune function in HCV+ individuals, and aid in the mitigation of associated negative clinical outcomes.